Key facts
- It has raised $660K; the latest was Early Stage VC ($25.0M) in Oct 2025.
- Notable investors include Melbourne Angels, Perth Angels.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Esfam Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Esfam Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Esfam Biotech
Operator of a biotech company intended to target human and animal diseases in the areas of oncology and viral infections. The company focuses on developing anti-cancer treatments against other common poorly responsive cancers, such as pancreatic, ovarian, kidney, lung, colorectal, melanoma, and breast cancer, enabling patients by conducting molecular research on significant diseases affecting global populations today.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2015
- Employees
- 6
- Website
- mlsbio.com/
- Ownership
- Privately Held (backing)
Esfam Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Esfam Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Esfam Biotech in its N-PORT filings yet. We sweep new filings monthly.